Circio Holding ASA is a clinical stage company developing immune activators to target difficult-to-treat diseases. The company’s mission is to deploy vector-based technology to create a novel class of targeted, multi-functional circRNA medicines. It has established a cutting-edge circular RNA (circRNA) program and is collaborating with Prof Michael Uhlin and a team at the Karolinska Institutet in Stockholm with the intent to develop next generation RNA therapeutics for various applications.
The company also has a mutant RAS cancer vaccine program, with two collaborative clinical trials underway in the USA and Norway. It is currently looking at options for the financing of a phase 2 study for ONCOS-102, a genetically modified oncolytic adenovirus.
Company Details
- Employees
- 19
- Founded
- -
- Address
- Lilleakerveien 2 C, Oslo,0283,norway
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- targovax.com
- HQ
- Oslo
Circio Holding Asa Questions
Circio Holding Asa's website is targovax.com
Circio Holding Asa's LinkedIn profile is https://no.linkedin.com/company/circio
Circio Holding Asa has
19 employees.
View email and phone details for 19
employees at Circio Holding Asa.
Circio Holding Asa's industry is
Biotechnology Research
Circio Holding Asa's top competitors are
Lytix Biopharma,
Thor Medical Asa,
Ultimovacs Asa,
Nextera As,
Nykode Therapeutics,
Clexbio,
Bergenbio Asa,
Oncoinvent Asa,
Zelluna,
Externa.
Circio Holding Asa's categories are Biotechnology Research
Circio Holding Asa's founding year is 2010
